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Redox  regulation  plays  a key role  in several  physiopathological  contexts  and  free  radicals,  from  nitric
oxide  and  superoxide  anion  up  to other  forms  of  reactive  oxygen  species  (ROS),  have  been  demonstrated
to  be involved  in  different  biological  and  regulatory  processes.  The  data  reported  in the current  literature
describe  a  link  between  ROS,  inﬂammation  and  programmed  cell  death  that  is  attracting  interest  as
new  pathways  to  be  explored  and  targeted  for  therapeutic  purposes.  In this  light,  there  is  also  growing
attention  to the  involvement  of  this  link  in  the activity  of the  TNF-related  apoptosis  inducing  ligand
(TRAIL).  TRAIL  is a member  of  the TNF  ligands  super  family  able  to  mediate  multiple  intracellular  signals,
with  the  potential  to  lead  to a range  of  biological  effects  in different  cell  types.  In  particular,  the  hallmark
of  TRAIL  is the ability  to induce  selective  apoptosis  in  transformed  cells  leaving  normal  cells almost
unaffected  and  this  feature  has  already  opened  the  door  to several  clinical  studies  for  cancer  treatment.
Moreover,  TRAIL  plays  a role  in  several  physiological  and  pathological  processes  of  both  innate  andancer adaptive  immune  systems  and  of  the  cardiovascular  context,  with  a strong  clinical  potential.  Nonetheless,
several  issues  still  need  to be  clariﬁed  about  the  signaling  mediated  by TRAIL  to  gain  deeper  insight  into  its
therapeutic  potential.  In  this  light,  the  aim  of  this  review  is  to  summarize  the main  preclinical  evidences
about  the  interplay  between  TRAIL  and  redox  signaling,  with  particular  emphasis  to  the  implications  in
vascular  physiopathology  and  cancer.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The “redox signaling” is a complex regulatory process in
hich the signal is delivered through redox chemistry in order
o generate protective responses against oxidative damage and
estore the correct redox-balance between reactive oxygen species
ROS) production and their clearance by anti-oxidative/scavenging
echanisms (Droge, 2002). In this light, the original deﬁnition
f oxidative stress refers to an unbalanced condition, resulting
rom excessive production of ROS and reactive nitrogen species
RNS) that antioxidant defense systems are not able to counter-
ct, leading to accumulation of reactive species that play a role
n several pathological contexts including inﬂammation, cardio-
ascular pathologies, atherosclerosis, metabolic alterations and
ancer (Montezano and Touyz, 2012a; Panieri and Santoro, 2016).
onetheless, the concept of oxidative stress is far more complex
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and its delineation has improved in the recent times with the aim of
including the role of redox signaling and reactive species/molecular
redox mediators, deﬁning a research ﬁeld connecting multiple
disciplines including chemistry, cell biology and physiopathology
(Sies, 2015). This new declination of the concept of oxidative stress
accounts for the increasing evidences of the involvement of reac-
tive species in key regulatory networks of physiological functions
such as regulation of vascular tone, insulin synthesis, activation
of hypoxia-inducible factor, cell proliferation, differentiation and
migration (Weidinger and Kozlov, 2015), suggesting that redox
biology might underlie and include both physiological and patho-
logical contexts (Schieber and Chandel, 2014). In the absence of
a widely accepted system for classiﬁcation of oxidative stress, a
“intensity-based” classiﬁcation has been proposed, highlighting the
role of the dose/concentration of the “stress-inducer” in relation
to molecular/biological endpoint parameters evaluated that reﬂect
the modiﬁcations induced by ROS (Sies, 2015; Lushchak, 2014).In this context, the endothelium represents a biological milieu
that in normal conditions maintains its integrity and function-
ality through a tight balance between opposite signals and
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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athways including anti/pro-oxidative, anti/pro-vasodilators,
nti/pro-inﬂammatory, anti/pro-thrombotic, anti/pro-
roliferative signaling (Vanhoutte et al., 2009). In the recent
ears, several in vitro and in vivo reports have demonstrated
hat the tumor necrosis factor-related apoptosis inducing lig-
nd (TRAIL) plays an important role in vascular physiology by
riggering different pathways, with a protective effect on the
ascular walls and on endothelial barrier function. However, con-
icting results emerge since TRAIL is a molecule able to activate
ro-apoptotic/pro-inﬂammatory pathways but also pro-survival
nd anti-inﬂammatory cell signals. This duality is a hallmark of
he TRAIL activity and the data reported about the role of TRAIL
n atherogenesis represent a paradigm of this feature (Cheng
t al., 2014). In fact, while a possible protective effect of TRAIL
as emerged from preclinical and clinical studies (Di Bartolo
t al., 2011; Secchiero and Zauli, 2012), high TRAIL levels might
esult in a detrimental effect on vascular integrity leading to
 pro-atherogenic condition, perhaps by enhancing leukocytes
dhesion and local inﬂammatory processes in a pathogenic loop
upporting plaques formation (Michowitz et al., 2005), leaving
till partially unclear the mechanisms underlying these effects.
n the contrary, in the context of cancer, recombinant soluble
RAIL already represents an appealing therapeutic option that is
nder evaluation at the clinical level for the treatment of different
ypes of tumor (Stuckey and Shah, 2013; Gasparini et al., 2013;
emke et al., 2014). However, even though encouraging results are
oming from the assessment of its therapeutic potential, several
ssues still need to be addressed such as the need to enhance
RAIL antitumor activity in order to overcome the heterogeneous
ensitivity of tumors and to restore the cell sensitivity to TRAIL in
he presence of TRAIL-resistance mechanisms.
Intracellular reactive species and components of the redox sig-
aling could be critical in regulating the response to TRAIL in
ifferent physiopathological contexts. In this light, it is of interest
hat ROS can inﬂuence induction of apoptosis mediated by CD95
nd TRAIL by affecting expression and distribution of cell recep-
ors, making the connection between redox signaling and death
eceptors an important mechanism of cell regulation with signif-
cant implications. In this context, in order to shed light on the
nterplay between TRAIL and oxidative pathway, we set out this
eview to summarize the main preclinical evidences of this inter-
ction focusing on two of the main physiopathological contexts of
he TRAIL activity: the vascular/endothelial compartment and the
umor setting. Moreover, we will review and discuss the key sug-
estions coming from the assessment of the cross talk between
RAIL and redox signaling in order to understand the “TRAIL biol-
gy” in terms of molecular mechanisms of action and strategies to
xploit the potential of TRAIL as therapeutic molecule.
. Overview on TRAIL signaling and biology
TRAIL is a member of the TNF ligand super family that can
e described as a pleiotropic molecule able to mediate multiple
ntracellular signals with the potential to lead to different (quite
ften contradictory) biological effects. This feature of TRAIL clearly
merges from both preclinical results and clinical studies highlight-
ng the “dual-role” of this protein in several pathological conditions,
panning from immunological/cardiovascular disorders to cancer.
iscovered independently by two groups more than 20 years ago
Wiley et al., 1995; Pitti et al., 1996), several subsequent in vitro
nd in vivo functional studies showed that TRAIL (also referred as
po2, CD253 and TNFSF10) was able to trigger cell apoptosis in
umor cells or infected/transformed cells while leaving substan-
ially unaffected normal cells (Ashkenazi et al., 1999; Walczak et al.,
999). Although this concept of selective pro-apoptotic activityemistry & Cell Biology 81 (2016) 364–374 365
has been revised during time as it has been reported that also
some normal cells can be affected by TRAIL (Vanhoutte et al., 2009;
Ursini-Siegel et al., 2002; Nesterov et al., 2002; Hayakawa et al.,
2004; Janssen et al., 2005; Zauli et al., 2009). TRAIL is expressed in
a wide range of tissues in both healthy and disease conditions and,
in common with other members of the TNF family, can be detected
as trans-membrane type protein and as soluble protein (Liabakk
et al., 2002). Once expressed, the protein can be cleaved and act
as soluble molecule through the generation of circulating trimers
that represent the biologically active form of TRAIL via interaction
with a system of ﬁve receptors which can be bound with different
afﬁnities (Orlinick and Chao, 1998; Yerbes et al., 2011). In partic-
ular, the TRAIL-receptor system comprises: two transmembrane
pro-apoptotic death receptors (DRs) named TRAIL-R1 (DR4) and
TRAIL-R2 (DR5) displaying full-length intracellular death domain,
two transmembrane decoy receptors named TRAIL-R3 (DcR1) and
TRAIL-R4 (DcR2) lacking an intact death domain and the soluble
decoy receptor osteoprotegerin (OPG) lacking both transmem-
brane and cytoplasmic domains (Orlinick and Chao, 1998; Yerbes
et al., 2011; Falschlehner et al., 2009). It is of interest that mRNA
of all transmembrane receptors can be detected in virtually all
tissues, while cell surface TRAIL protein expression is more cell-
dependent. As mentioned before, the most intriguing feature of
TRAIL is its ability to induce apoptosis mainly in cancer and in
transformed/infected cells by interacting with DR4 and DR5. The
TRAIL-mediated apoptosis pathways have been already reviewed
in details (Falschlehner et al., 2007), brieﬂy after binding to DRs,
induction of apoptosis requires the assembly of a death-inducing
signaling complex (DISC) at membrane level characterized by the
clustering and oligomerization of intracellular death domains with
the recruitment of the Fas-Associated Death Domain (FADD) and
caspases-8 and -10 that are recruited and undergo autocatalytic
processing followed by caspases cascade activation (Sessler et al.,
2013) (Fig. 1A). In addition to caspases-mediated extrinsic apop-
totic process, there is also an intrinsic apoptotic signaling triggered
by the cleavage of the BH3-only protein to truncated Bid (tBid)
that mediates the activation of Bax and Bak at the mitochondrial
level with release of Cytochrome-C and pro-apoptotic proteins
(Falschlehner et al., 2007; Sessler et al., 2013) (Fig. 1A).
Activation of TRAIL death receptors may  also trigger non-
apoptotic and pro-survival/proliferation signals such as those
mediated by the mitogen-activated protein kinases (MAPKs),
PI3K/Akt and ERK pathways and by the transcription factor nuclear
factor-B (NF-B), all involved in the regulation of developmen-
tal and inﬂammatory processes (Di Pietro and Zauli, 2004; Zauli
et al., 2005) (Fig. 1A). Finally, as well as other pro-apoptotic signals,
TRAIL can also lead to necroptosis, a regulated and programmed
form of necrosis put in place as response to severe stress and in the
presence of blocked normal apoptosis (Jouan-Lanhouet et al., 2012;
Chen et al., 2016). A comparison between apoptotic and necroptotic
processes has been recently addressed and reviewed, highlighting
the role of the different necroptotic regulators and pathways (Chen
et al., 2016; Fuchs and Steller, 2015). In particular, the formation
of the necroptotic-complex following stimulation is mediated by
speciﬁc kinases (RIPK1 and RIPK3), that are in turn involved in the
phosphorylation of the mixed lineage kinase domain like protein
(MLKL), triggering the induction of downstream processes lead-
ing to cell death such as alteration of osmotic pressure and plasma
membrane rupture (Fig. 1A). It has been suggested that Caspase-
8 might be one of the key factors in mediating the execution of
either apoptosis or necrosis. Caspase-8 is able to block necropto-
sis by cleaving RIPK1 and RIPK3 in favor of the apoptotic process
while in the presence of Caspase-8 inhibitors and/or compromised
Caspase-8 activity there is an inhibition of apoptosis in favor of the
necroptotic signaling. Although the mechanisms down-streaming
MLKL during necroptosis still remain to be clariﬁed, it becomes
366 R. Voltan et al. / The International Journal of Biochemistry & Cell Biology 81 (2016) 364–374
Fig. 1. Schematic representation of TRAIL-mediated apoptotic, pro-survival and necroptotic signaling. After binding to its receptors, TRAIL can initiate cell apoptosis, necrop-
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tosis  or lead to cell survival. In A, the main molecular mediators involved in TRAIL-
via  caspases activation) and necroptosis (via RIPK1-3 and MLKL) are shown. In B, a 
poptosis through the mediation of ROS and ASM production is shown. ROS are rea
lear that the possibility of promoting necroptosis in cancer cells
epresents an attractive therapeutic strategy with a strong clinical
otential that deserve more investigations, in particular in light of
he evidence that resistance to apoptosis is one of most challenging
allmarks of cancer.
TRAIL plays a critical role in modulating the immune system and
his feature has been extensively explored in the context of diabetes
ellitus (DM) (Bossi et al., 2015). In particular, both preclinical and
linical reports on Type-1 DM suggest a protective effect of TRAIL,
robably through the regulation of central and peripheral toler-
nce carried out through a modulation of T-cells activity achieved
nducing T cell apoptosis and expansion of regulatory T cells (Zauli
t al., 2010; Bernardi et al., 2012a; Tornese et al., 2014, 2015). In the
ame fashion, TRAIL can control Type-2 DM by contrasting fat mass
ncrease and inducing anti-inﬂammatory effects (Bernardi et al.,
012b; Bisgin et al., 2012; Xiang et al., 2014). The evidence that
atients affected by several diseases show altered circulating TRAIL
evels highlights the involvement of TRAIL in the onset/progression
f the diseases suggesting a clinical potential of this molecule as a
isease biomarker or as therapeutic option. Our group has signiﬁ-
antly contributed to the demonstration of an inverse correlation
etween circulating TRAIL levels and pathological conditions char-
cterized by chronic inﬂammation. Low TRAIL levels are associated
ith total and cardiovascular mortality in older adults (Volpato
t al., 2011), and with poor outcome in patients affected by other
athological conditions such as myocardial infarction, coronary
yndrome, heart failure and chronic diseases (Secchiero et al., 2009,
010a; Niessner et al., 2009; Liabeuf et al., 2010; Osmancik et al.,
013; Brombo et al., 2013). Overall, these studies have suggested
hat TRAIL might have a role in vascular protection and control
f inﬂammation (Secchiero et al., 2013). As regard to the regula-
ory mechanisms of TRAIL expression, a role has been identiﬁed
or 17-estradiol that could be involved down regulating the cir-
ulating levels of TRAIL (Zauli et al., 2014). Other hypotheses for
he low TRAIL levels detected in several pathological settings, in
articular in the context of cardiovascular diseases, might be due
o the simultaneous increase of circulating OPG and/or to alter-
tions of other biological parameters such as the balance between
etalloproteinase-2 and tissue inhibitor of metalloprotease-2 that
as been proposed to be involved in the clearance of circulating
RAIL (Secchiero et al., 2010b). Nevertheless, as previously men-
ioned for atherosclerosis, conﬂicting results have been reportedted pathways leading to cell survival (via NF-B and kinases activation), apoptosis
l of aggregation of TRAIL receptors in lipid rafts leading to enhanced TRAIL-induced
xygen species; ASM is acid sphingomyelinase; DR are death receptors.
on the role of TRAIL also for rheumatoid arthritis (Audo et al.,
2013), allergic asthma (Tisato et al., 2014; Collison et al., 2014) and
inﬂammatory disorders of the CNS likely as the result of differ-
ent involvement/effects of TRAIL pathways in local and peripheral
inﬂammatory processes (Tisato et al., 2016). Overall, the emerging
picture describes TRAIL as a molecule able to trigger a multifaceted
system of biological effects and functions, as result of a complex
ligand receptors’ system and of multiple levels of signal modula-
tion/control that are put in place according to the speciﬁc cell type
and to the speciﬁc biological/pathological contexts. In this line, cur-
rent data suggest that DRs are deﬁnitely more than simply receptors
involved in triggering an apoptotic signal, since their activation can
lead to a wide panel of cellular responses. The ability of DRs to
mediate conﬂicting cell signals might be also the result of the redis-
tribution of DRs themselves at the cell membrane surface of target
cells, with important biological and therapeutic implications. The
distribution of the different receptors could account for the selec-
tive activity of TRAIL, which might be controlled by the temporal
and local redistribution of its receptors. In fact, the functionality
of ligand receptors, such as those for TRAIL, involves their phys-
ical association at the membrane level through the generation of
membrane domains deﬁned “rafts”. These membrane domains play
a key role in the transduction of the extracellular signals inside the
target cell and have a strong potential as a target for new strategies
to control cell death and overcome TRAIL-resistance (Delmas et al.,
2004).
2.1. TRAIL and redox pathways interplay: role in vascular cells
biology
2.1.1. TRAIL/TRAIL-receptors and endothelium
The selective mechanisms mediated by TRAIL leading to apo-
ptosis almost exclusively of cancer cells and to activation of
non-apoptotic pathways are still unclear (Baker and Reddy, 1996;
Zhang et al., 2000; Pritzker et al., 2004; Ashkenazi and Herbst,
2008). In this line, the ongoing literature clearly documents that
also in the context of vascular physiopathology the role of TRAIL
remains controversial, with an overall message coherent with the
“dual-face” nature of this protein. TRAIL is expressed in vascu-
lar smooth muscle cells (Gochuico et al., 2000), and although the
expression of TRAIL protein at the endothelial level is still a con-
tentious issue (Vaccarezza et al., 2007; O’Brien et al., 2007), the
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resence of all TRAIL receptors in these cells is able to mediate
 broad range of reactions upon stimulation by TRAIL, includ-
ng inﬂammation, apoptosis, cell proliferation and differentiation
Zauli and Secchiero, 2006; Cantarella et al., 2014). On the other
and, the clinical evidence that circulating TRAIL levels correlate
ith several pathological conditions with a vascular component
upports the involvement of TRAIL in the onset/progression of these
iseases, with different visions about its role (Tisato et al., 2013;
arper et al., 2016; Forde et al., 2016). In this context, our group
as contributed to the demonstration that TRAIL is able to promote
urvival and proliferation of primary human endothelial cells (Zauli
t al., 2009; Secchiero et al., 2003). In particular, the pro-survival
ignals are mediated by phosphorylation of the serine/threonine
inase Akt via PI3K activation and by the stimulation of ERK1/2
athway (Secchiero et al., 2003). In fact, in different in vitro stud-
es, the inhibition of phosphatidylinositol 3-kinase (PI3K) was  able
o reduce P-Akt, with a concomitant reduction of Bcl-2 leading
o the sensitization of the endothelium to TRAIL-mediated apo-
tosis via extrinsic and intrinsic pathways (Secchiero et al., 2003;
lladina et al., 2005). Moreover, we have also demonstrated that
RAIL down modulates the interaction/adhesion between leuko-
ytes and endothelial cells, counteracting the pro-adhesive activity
f both TNF- and IL-1 by selectively down-regulating CCL8 and
XCL10 chemokines, with both TRAIL-R1 and TRAIL-R2 playing a
ole in the TRAIL-mediated effects (Secchiero et al., 2005).
.1.2. TRAIL and ROS in endothelium
Impaired/inefﬁcient activity of antioxidant systems such as
ndothelial-derived vasodilators may  leads to ROS accumulation,
ell damage and to a variety of pathological lesions (Sies, 1997; Cai
nd Harrison, 2000). In this respect, there is a widely accepted link
etween oxidative stress and inﬂammation at the vascular level,
eading to endothelial cell dysfunctions (e.g. compromised ability
o regulate the vascular tone and altered pro-coagulant and anti-
nﬂammatory capacities), which are features of atherosclerosis and
ascular diseases (Ross, 1999; Higashi et al., 2014; Siti et al., 2015).
ajor sources of cellular ROS include the mitochondrial respiratory
hain and enzymatic reactions mediated by enzyme systems such
s xanthine oxidoreductase, nitric oxide (NO) synthase (NOS) and
icotinamide adenine dinucleotide phosphate (NADPH) oxidases.
he physiological and pathological relevance of these sources is dif-
erent depending on the speciﬁc disease and tissue/organ. Within
he enzymes responsible for ROS production, NADPH oxidases,
anthine oxidases and (uncoupled) NOS are of particularly impor-
ance in the endothelial/vascular compartment. At vascular level,
rimary ROS products, mainly superoxide (O2−) and hydrogen per-
xide (H2O2), are indeed involved in a broad range of cellular
unctions related to endothelial functions/dysfunctions and vas-
ular functional integrity including cytoskeletal regulation, cell
roliferation, differentiation, migration and apoptosis (Lassegue
nd Griendling, 2010; Montezano and Touyz, 2012b; Raaz et al.,
014). A key role in endothelial cell biology and cardiovascular
omeostasis is played by NO, a RNS synthetized from L-Arginine
nd involved in the regulation of the vascular tone, and anomalies in
he production/bioavailability of NO are features of endothelial dys-
unctions associated to cardiovascular diseases (Zhao et al., 2015).
t endothelial level NO modulates several processes, including
latelet aggregation, leukocyte adhesion, vascular smooth muscle
ell proliferation and angiogenesis (Moncada et al., 1991; Dimmeler
nd Zeiher, 1999; Dimmeler et al., 1999; Fisslthaler et al., 2000;
asa et al., 2000; Weiland et al., 2000). In this respect, our group
as demonstrated that TRAIL is able to induce the production of
O upregulating endothelial NOS (eNOS, the most important enzy-
atic source of NO in vascular endothelial cells), by activating of the
kt/eNOS pathway and increasing the production of prostanoids
ia cyclooxygenase-1, conferring to the cells a proangiogenic andemistry & Cell Biology 81 (2016) 364–374 367
anti-inﬂammatory phenotype (Zauli et al., 2003). However, at the
same time, in in vitro endothelial cell systems other groups showed
that TRAIL was  also able to trigger FADD-caspase-8-dependent
apoptosis together with the induction of inﬂammatory pathways
including NF-B activation and E-selectin, ICAM-1, and IL-8 expres-
sion (Li et al., 2003). In the same fashion, in their work Pritzker and
colleagues demonstrated that TRAIL was  able to induce apoptosis
in human microvascular endothelial cells while its decoy receptor
OPG acted as survival factor (Pritzker et al., 2004). More recently in
the pathological context of Alzheimer’s disease, the pro-apoptotic
death receptors DR4 and DR5 were shown to mediate the induction
of extrinsic apoptotic pathway with activation of both caspase-8
and caspase-9 in human microvascular cerebral endothelial cells
(Fossati et al., 2012). Taken together these data overall suggest that,
at the endothelial level, TRAIL might have the ability to promote
opposite signaling pathways acting either as pro-apoptotic sig-
nal or as pro-survival/anti-apoptotic/anti-inﬂammatory stimulus,
encouraging the ongoing discussion.
2.1.3. TRAIL-receptors and ROS in endothelium
The reported contrasting effects mediated by TRAIL, in both nor-
mal  and pathological conditions, have been also associated to the
concept of the so called “lipid rafts”, more recently designed as
“membrane raft” (MR). MR  are dynamic cell membrane domains
based on cholesterol, proteins and sphingolipids/sphingolipids-
metabolites that are able to mediate several cell functions (Zhang
et al., 2009). The MR  constitution is strictly related to the genera-
tion of ceramide via hydrolysis of membrane sphingomyelin by acid
sphingomyelinase (ASM), a key event that signiﬁcantly modify both
cell membrane constitution and properties through the mutual
interaction between sphingolipids and between sphingolipids and
cholesterol resulting in the formation of distinct membrane-area.
The fusion of different small ceramide-rich membrane areas leads
to the generation of more large ceramide-enriched membrane plat-
forms that organize the local and temporal distribution/clustering
of cell receptors and signaling molecules driving in this way  the
transmission of speciﬁc cell signals and the modulation of the asso-
ciated cell-pathways amplifying receptor- and stress-mediated
signaling events (Zhang et al., 2009). It is of interest that there
is a speciﬁc link between ceramide-mediated MR constitution
and redox signaling at the vascular level with a crucial role of
ceramide in amplifying redox signaling in endothelial cells leading
to endothelial dysfunction (Li et al., 2010; Jin et al., 2011). In this
respect, it has been shown that ceramide-reach platforms have an
impact in ROS production since they are able to recruit and acti-
vate key molecules involved in ROS production such as the NADPH
oxidase family, gp91phox, p47phox, Rac GTPase (Zhang et al., 2006,
2007; Jin et al., 2008). Moreover, the formation of MR-redox signal-
ing platforms in endothelial cells is associated with a production of
ceramide, mediated by lysosomal ASM that translocate at the cell
membrane level after lysosomal trafﬁcking in response to death-
receptors activation (Bao et al., 2010a,b).
In the context of TRAIL, the generation of speciﬁc lipid rafts
seems to be one of the possible mechanisms of action by which
this ligand is able to trigger different cellular pathways with so
different cellular effects. TRAIL has been demonstrated to acti-
vate ASM via a redox mechanism resulting in release of ceramide
and formation of ceramide-enriched membrane platforms that
are involved in the clustering of DR5, that amplify TRAIL-DR5
signaling (Dumitru and Gulbins, 2006) (Fig. 1B). In fact, in their
study Dumitru and colleagues showed that antioxidants were able
to prevent ASM stimulation and the release of ceramide follow-
ing TRAIL treatment, leading to abrogation of ceramide-enriched
membrane platforms formation and inhibiting TRAIL-induced
apoptosis (Dumitru and Gulbins, 2006). More recently, Li and col-
leagues addressed the interaction between TRAIL signaling and cell
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embrane re-organization processes in the context of endothelial
ells (Li et al., 2013). In a model of murine coronary arterial endothe-
ial cells (CAECs), the authors showed that TRAIL was  able to induce
he formation of redox-MR platforms with activation of NADPH
xidase and production of O2−, leading to endothelial dysfunction
nd vasodilatation (Li et al., 2013). The proposed model highlights
R4 as the TRAIL receptor involved and responsible, upon activa-
ion, of an early-stage and acute effect through the induction of
he assembly and activation of NADPH oxidase in MR  clusters. In
articular, the authors showed that TRAIL was able to trigger the
usion of lysosomes with the cell membrane with the formation of
R redox platforms rich in ceramide leading to impaired endothe-
ial functions. Of interest, the results obtained in the same model
ut in a context of ASM-deﬁciency conﬁrmed the key role of ASM in
ediating the TRAIL/DR4-induced formation of the redox-MR plat-
orms and the subsequent endothelial dysfunction. The reported
ell alterations were associated to increased O2− levels, leading to
 reduced availability of NO with deﬁciency on vasodilatation (Li
t al., 2013).
In contrast to the cytotoxic effect of TRAIL associated with ROS
roduction, it has been nonetheless reported that ROS might be
nvolved in TRAIL-induced protective and anti-apoptotic effect. Di
artolo and colleagues have recently reported the results of a study
iming at understand the mechanisms of TRAIL in inducing angio-
enesis and neovascularization (Di Bartolo et al., 2015) showing
hat NADPH enzymes, the key factors for ROS production in vas-
ular cells, might trigger other biological effects. In a model of
ngiogenesis following hind limb ischemia, the authors reported
 proangiogenic effect of TRAIL as downstream regulator of FGF-
, and highlighted the link between the NADPH oxidase-4 and
O signaling. In particular, endothelial cell proliferation, migration
nd tubule formation upon TRAIL stimulation were dependent on
2O2 and eNOS-derived NO signals (Di Bartolo et al., 2015). As the
uthors suggest in the discussion, the different results obtained in
heir model compared to the ﬁndings reported by Li and others,
ight be due to the activation of speciﬁc NADPH oxidase isoforms.
n this light, in a non-endothelial model it has been demonstrated
hat both DR4 and DR5 can activate NADPH oxidase-1 and trigger
n apoptotic pathway via riboﬂavin kinase recruitment, following
n alternative mechanism of signal transduction from the conven-
ional DISC-mediated apoptosis (Park et al., 2012).
Several reports have indeed highlighted that NADPH oxidases
ctivation by high glucose leads to increased ROS production with
ndothelial damage/dysfunction, and alteration of the integrity
f the endothelium by reducing NO bioavailability (Bonnefont-
ousselot, 2002; Nakagami et al., 2005; Yu and Lyons, 2005). In
his context, Liu and co-workers have recently demonstrated that
ecombinant TRAIL signiﬁcantly attenuated endothelial cell apo-
tosis and oxidative stress induced by high glucose in both in in vitro
nd in vivo experimental models (Liu et al., 2014). In particular,
RAIL was able to suppress superoxide production in an in vivo
odel of high-glucose stress by inducing a signiﬁcant increase of
uperoxide dismutase (SOD) activity. Moreover, the in vitro data
howed that TRAIL reduced high-glucose mediated ROS produc-
ion by suppressing NADPH oxidase activity and by increasing the
xpression of protective factors including SOD2 and GPx-1. Sig-
al pathways studies ﬁnally suggested that TRAIL treatment could
ttenuate the damage induced by diabetes at the endothelial level
hrough the involvement and activation of the PI3K-Akt-eNOS sig-
aling pathways (Liu et al., 2014).
Overall, the link between TRAIL and NO through the PI3K-Akt-
NOS signaling pathways appears one of the molecular networks
nvolved in the protective role of TRAIL as supported by differ-
nt groups of investigators. Nonetheless, the interaction between
RAIL and ceramide emerges as well as a critical signaling path-
ay in regulating the biological effects at endothelial level. Inemistry & Cell Biology 81 (2016) 364–374
particular, deeper insight into the cross talk between TRAIL and
redox signals, in MR platform formation and in TRAIL-receptors
clustering processes are needed together with a better understand-
ing of the mechanisms of action of TRAIL in relation to the different
NADPH isoforms and ROS generation pathways.
2.2. TRAIL and redox pathways interplay: role in tumor biology
2.2.1. TRAIL/TRAIL-receptors and tumors
In the ﬁeld of cancer therapy, TRAIL has obtained in recent
years tremendous interest due to its ability to induce apopto-
sis in malignant tumor cells without affecting normal cells. This
feature, observed in several in vitro and in vivo model systems
of both solid and hematopoietic cancers, indicates TRAIL is an
ideal anti-cancer drug (Walczak et al., 1999; Holoch and Grifﬁth,
2009; de Miguel et al., 2016). On these bases, several researchers
developed pharmacologic strategies, using recombinant TRAIL or
TRAIL-receptor agonists (TRAs), to exploit the potential of TRAIL in
clinical anticancer applications (Lemke et al., 2014). While these
therapeutic approaches are under evaluation in phase I/II clinical
studies (Table 1), two  major issues still limit the clinical translation
of TRAIL: the evidence that some tumors are TRAIL-resistant and
that cancers can develop acquired resistance to TRAIL. The mech-
anisms by which cancer cells escape TRAIL-induced apoptosis are
several (Buneker et al., 2009; Trivedi and Mishra, 2015) and innova-
tive approaches to overcome TRAIL resistance are currently deeply
investigated. Of interest, a growing number of studies indicates that
TRAIL resistant cancer cells can be re-sensitized by using several
agents (natural and synthetic compounds, FDA-approved drugs)
targeting speciﬁc intracellular pathways (Trivedi and Mishra, 2015;
Farooqi et al., 2015). Following this recent therapeutic view, a
therapeutic approach based on the combination of TRAIL plus a
re-sensitizing agent is at present the best opportunity to improve
the TRAIL anti-tumor activity.
2.2.2. Death receptors and inﬂammation in cancer
Following the concept that TRAIL exerts its activity not only by
inducing cell apoptosis but also by modulating other key cellular
pathways such as those involved promoting inﬂammation, alter-
native cell signaling have been considered and investigated also in
the context of cancer (Trivedi and Mishra, 2015; Cullen and Martin,
2015). The engagement of TRAIL receptors (and Fas) can drive the
production of pro-inﬂammatory cytokines and chemokines after
NF-B activation (Zauli et al., 2005; Trauzold et al., 2001; Siegmund
et al., 2005; Berg et al., 2009), with important implications for
several disease linked to chronic and acute inﬂammation and for
cancer biology (Trivedi and Mishra, 2015; Chen et al., 2010). Con-
sidering that NF-B activation and protein translation are inhibited
during the apoptotic process, the non-apoptotic effects of TRAIL
are more evident in apoptosis-resistant cells that can acquire
metastatic/invasive potential, as shown in several tumor types such
as in pancreatic ductal adenocarcinoma (Trauzold et al., 2006),
cholangiocarcinoma (Ishimura et al., 2006), melanoma (Takahashi
et al., 2013) and breast cancer (Wang et al., 2014). Besides, in
addition to its anticancer role, TRAIL might also promote the inﬂam-
matory tumor microenvironment. In this light, a relevant paper of
Berg and colleagues shows that TRAIL activates pro-inﬂammatory
pathways in 50% of primary myeloma samples, emphasizing the
evidence that TRAIL should be used in combination with anti-
inﬂammatory drugs to reduce the pro-inﬂammatory effects of the
molecule (Berg et al., 2009). Coherently with this suggestion, it
has been demonstrated that NF-B activation can promote the
expression of interleukins (such as IL-1, IL-8 and IL-6) that exert
a growth promoting effect on the tumor, even though the role
of NF-B is still controversial in some tumor types (Ben-Neriah
and Karin, 2011). Cullen and colleagues reported a different role
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Table  1
Clinical trials with agonistic antibodies or soluble TRAIL reported on www.clinicaltrials.gov.
Cancer n Combination Phase Status Identiﬁer n◦
Conatumumab (AMG  655)
Colon 202 Modiﬁed FOLFOX6, Bevacizumab, Placebo I/II C NCT00625651
Colon 53 Panitumumab I/II C NCT00630786
Colon 155 AMG  479, FOLFIRI, Placebo II C NCT00813605
Colon 12 AMG  479, Ganitumab, Bevacizumab II A (nr) NCT01327612
Colon, Lung, Ovarian, Pancreatic, Sarcoma 89 AMG  479 I/II T NCT00819169
Hodgkin’s lymphoma, NHL 33 Vorinostat, Bortezomib I C NCT00791011
Lung 172 Paclitaxel, Carboplatin I/II C NCT00534027
Ovarian, Peritoneal, Falopian Tube 27 Birinapant I C NCT01940172
Pancreatic ND Capecitabine, Gemcitabine, Hydrochloride, Radiation I/II W NCT01017822
Pancreatic, Adenocarcinoma 138 AMG  479, Placebo I/II C NCT00630552
Sarcoma 134 Placebo, Doxorubicin I/II C NCT00626704
AMG  951 (rhAPO2L/TRAIL)
Lung 213 Bevacizumab, Carboplatin, Paclitaxel II C NCT00508625
Tigatuzumab (CS-1008)
Breast 66 Abraxane II A (nr) NCT01307891
Colon 19 Different variants of tigatuzumab antibody I C NCT01220999
Colon 21 FOLFIRI I C NCT01124630
Colon 8 Irinotecan II T NCT00969033
Liver, Hepatic 172 Sorafenib II C NCT01033240
Lung 109 Paclitaxel, Carboplatin, Placebo II C NCT00991796
Lymphoma 40 alone I C NCT00320827
Ovarian 24 Paclitaxel, Carboplatin II C NCT00945191
Pancreatic 65 Gemcitabine II C NCT00521404
Dulanermin
Colon 23 Bevacizumab, FOLFOX I C NCT00873756
Colon 42 FOLFIRI, Bevacizumab, Cetuximab, Irinotecan I C NCT00671372
NHL  72 Rituximab I/II T NCT00400764
Lexatumumab
Sarcoma, Neuroblastoma 19 Interferon Gamma  1b I T NCT00428272
Mapatumumab (HGS-ETR1)
Carcinoma, Hepatocellular 23 Sorafenib I C NCT00712855
Carcinoma, Hepatocellular 101 Placebo, Sorafenib II A (nr) NCT01258608
Cervical 9 Cisplatin, Radiotherapy I/II C NCT01088347
Lung 111 Paclitaxel, Carboplatin II C NCT00583830
Multiple Myeoloma 105 Bortezomib II C NCT00315757
Drozitumab (PRO95780)
Chondrosarcoma 90 Alone-No combinations II T NCT00543712
Colon 20 Bevacizumab, Cetuximab, FOLFIRI, Irinotecan I C NCT00497497
Colon 9 Bevacizumab, FOLFOX I C NCT00851136
Lung 128 Bevacizumab, Carboplatin, Paclitaxel, Placebo II C NCT00480831
NHL  49 Rituximab II C NCT00517049
TAS266 (Tetravalent Nanobody)
Advanced Solid Tumor 6 Alone-No combinations I T NCT01529307
TRAIL-R1 Mab
Lung, Carcinoma ND Alone-No combinations II C NCT00092924
NHL  ND Alone-No combinations II C NCT00094848
N wn; M
n
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aHL: non-Hodgkin lymphoma; C: Completed, A: Active; T: terminated; W:  Withdra
umber of patients enrolled not declared.
or DR-induced chemokines, introducing the concept that cells
ying by pro-apoptotic signals mediated by Fas, TNF and TRAIL
re not immunologically silent and may  release factors able to
oordinate the removal of dying cells by phagocytes (Cullen et al.,
013). The authors reported in particular the activation of a pro-
nﬂammatory program, uncoupled from caspases activity and cell
eath, that results in the secretion of an array of chemokines and
ytokines triggering chemotaxis toward dying cells. Their discov-
ry suggested a sort of “ﬁnd-me” signal originating from apoptotic
ells and showed for the ﬁrst time the DR-induced cell death as an
mmunologically active process.
It becomes clear that the role of TRAIL is complex and multi-
aceted also in the context of cancer, and the classiﬁcation of TRAIL
nd Fas receptors as “death receptors” appears as an oversimpliﬁca-
ion since their activation is not merely cell apoptosis induction but
lso cytokines/chemokines production and control of cell functionsab: monoclonal antibody; nr: not recruiting; n: number of patients enrolled; ND:
such as proliferation, migration and differentiation. To take into
account this complexity is therefore mandatory during the design
of new anticancer therapies based on TRAIL in combination with
synergistic agents, in particular to avoid pro-tumoral side effects in
the case of TRAIL-resistant tumors. Moreover, it has to be consider
that recent literature has shown that the majority of intracellu-
lar mechanisms of TRAIL resistance implicates disturbance of the
oxidative stress “homeostasis”.
2.2.3. TRAIL and ROS in cancer
Looking for intracellular targets that might help TRAIL anti-
cancer activity, there is growing interest in the interplay between
TRAIL-mediated signaling and oxidative stress responses. The link
between oxidative stress and cancer is not a recent discovery, but
the crosstalk with the TRAIL pathway has a more recent origin. Pre-
vious observations about the activation of NOS pathway in parallel
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iig. 2. Redox signaling and TRAIL biological activity. The picture shows some of t
ctivity. NO is nitric oxide; ROS are reactive oxygen species; ASM is acid sphingom
eductase; DRs are death receptors; NOX are NADPH oxidases; O2− is superoxide; H
o caspases cascade after TRAIL treatment were made by our group
n leukemic cells (Secchiero et al., 2001) and TRAIL and ROS were
nvestigated by other groups in different preclinical models of solid
ancer. For example, it has demonstrated that ER stress/ROS (H2O2
nd O2−) induction can result in the upregulation of DR5 in human
arcinoma cell lines (Yamaguchi and Wang, 2004) and, associated
o the downregulation of survivin, in TRAIL-resistant melanoma
ells (Tse et al., 2014). Moreover, regulation of DR4 and DR5 expres-
ion has been associated to ER-mediated apoptosis in human lung
ancer cells treated with ER stress inducing agents (DDIT3 and
AT2A) (Li et al., 2015). Several other reports indicate that TRAIL
eceptors DR4 and DR5 can be induced by ER stress, suggesting
hat ER stressor drugs, such as thapsigargin, can be used to sensi-
ized cells to TRAIL-mediated apoptosis (Iurlaro and Munoz-Pinedo,
016).
Other studies describe a different mechanism of interaction
etween TRAIL and redox signaling via cell membrane depolariza-
ion, due to impairment of ion channels or transporters of Na+, K+,
l− and Ca2+, and to disruption of intracellular ion homeostasis,
eading to apoptosis. Several human malignant tumor cells (includ-
ng melanoma, leukemia and lung cancer), but not normal cells,
how robust and persistent depolarization after TRAIL treatment
n a dose and time-dependent manner and in correlation with the
peciﬁc cell sensitivity to TRAIL-induced apoptosis (Suzuki et al.,
012; Inoue and Suzuki-Karasaki, 2013; Suzuki-Karasaki et al.,
014a). This type of depolarization has been described as an early
nd pro-apoptotic event induced also by other pro-apoptotic well
eﬁned agents such as Fas, rotenone and arsenic trioxide (Bortner
t al., 2001; Nolte et al., 2004; Yin et al., 2009), and it is associ-
ted with activation of the mitochondrial apoptotic pathway and
OS generation. In this line, the results reported by Suzuki-karasaki
Suzuki-Karasaki et al., 2014a) suggest the existence of a positive
oop between depolarization and mitochondrial-derived ROS (O2−)
ccumulation through DR5 expression, although the speciﬁc mech-
nism of modulation and the role of Na+-K−ATPase still need to be
eﬁned in the context of TRAIL-induced apoptosis. In this regard, a
ariety of compounds capable of further increase the intracellular
evels of ROS induced by TRAIL, in particular H2O2, has been shown
o have the capability to potentiate the TRAIL antitumoral efﬁcacy
n several tumor models (Suzuki-Karasaki et al., 2014a,b) and offerslecular mediators of the cross talk between redox signaling and TRAIL biological
se; SOD is superoxide dismutase; ER is endoplasmic reticulum; GSR is glutathione
s hydrogen peroxide; ONOO− is peroxynitrite.
increasing opportunity of therapy. Of interest, also several natural
pharmacological agents have shown the potential to sensitize can-
cer cells to TRAIL apoptotic activity via ROS production and the
evidence that they are able to upregulate TRAIL-DRs makes them
an appealing therapeutic option to be explored also at the clini-
cal level in combination with recombinant TRAIL or DRs-agonist
antibodies (Supplementary Table 1). Another key component of
the oxidative stress response, the enzyme Glutathione reductase
(GSR), has been shown to be involved in the TRAIL-mediated apo-
ptosis in melanoma and carcinoma cell lines of different origin
(prostate, pancreatic, lung and breast). In this setting, new com-
pounds, identiﬁed by high throughput screening and able to inhibit
the activity of GSR, with a concomitant drop of intracellular antiox-
idant reduced glutathione (GSH) and induction of oxidative stress,
have been shown to potentiate TRAIL toxicity in vitro and in mouse
xenograft models (Rozanov et al., 2015), offering another weapon
to support TRAIL anticancer skills.
The interplay between oxidative stress and TRAIL-induced apo-
ptosis has been also reported for speciﬁc NO-derived chemical
species, referring in particular to peroxynitrite, a highly reactive
free radical resulting from the rapid interaction between NO and
superoxide (Stamler et al., 1992). Once generated, peroxynitrite
acts as a potent oxidant able to trigger a wide range of effects culmi-
nating in cell dysfunction, apoptosis or necrosis (Virag et al., 2003)
and it has been suggested to be able to potentiate TRAIL-induced
apoptotic death (Lee et al., 2001). In addition, in a recent work Seah
and colleagues have highlighted the role of peroxynitrite in medi-
ating the TRAIL-mediated apoptotic effect in cisplatin-resistant
cancer cells (Seah et al., 2015). In line with previous ﬁndings, the
authors detected mitochondrial defects on cisplatin-resistant lung
and ovarian cancer cells compared to wild type (cancer) cells and
reported a higher susceptibility of these cells to TRAIL-induced
apoptosis. This effect on cisplatin-resistant cells was in particular
associated with a different re-destribution of DRs to lipid rafts on
the plasma membrane, increased iNOS expression with subsequent
NO generation by target cells highlighting the key role of peroxyni-
trite that appears to be required for maximal TRAIL-induced cell
death. It is of interest that this study suggests the presence of a
positive feedback loop with DRs activating caspases with increased
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NOS activity leading to NO release and peroxynitrite production
hat in turn amplify death execution (Seah et al., 2015).
Overall, there is increasing evidence suggesting that tumor cells
re more suitable than normal cells to oxidative stress and depolar-
zation and more exposed to mitochondrial network abnormalities
nd that this vulnerability can be relevant to the tumor-targeting
illing by TRAIL. Moreover, considering that: i) cancers can orig-
nate from chronically inﬂamed tissues (Reuter et al., 2010); ii)
nﬂammation is tightly regulated by the redox signaling (Lei et al.,
015) and that iii) increasing reports highlight the role of TRAIL
ignaling in both inﬂammation and redox modulation, there is
rowing attention to TRAIL as a key element able to talk with
nd modulate all these pathways. This feature, together with the
ro-apoptotic anticancer capability of TRAIL, can be tailored and
uided for several purposes. In particular, the synergy between
RAIL and molecules able to target one of the mentioned pathways
ill provide efﬁcacious combinations able to target and kill even
RAIL-resistant tumors while saving normal cells.
. Concluding remarks
While ROS were initially considered species responsible only for
ell damage and cell death, their role has been now revised in light
f their involvement in a more complex range of reactions including
ignal transduction pathways and regulation of several cell func-
ions. The attempt of deﬁning the speciﬁc type of oxidative stress
n each physiopathological and/or experimental context, perhaps
y using the proposed “intensity-based” classiﬁcation (Lushchak,
014), is still a challenging task since speciﬁc and strict guidelines to
iscriminate between different levels/ranges of oxidative stress are
eeded. In the context of TRAIL, there is growing interest in under-
tanding how reactive species and redox mediators can interfere
ith its pathways and mechanisms of action since these knowl-
dge might be used to improve and optimize its biological activity.
he binding of TRAIL to its surface receptors is far more that simply
aspases activation and the mechanisms of protection of normal
ells against apoptosis as well as the ability of activate opposite
athways leading to different biological outcomes are not clear and
eed further insights. In this light, the concept of membrane traf-
cking and the demonstration of a cross talk between oxidative
ystem and ASM pathway in DR-mediated signaling activation has
hed some light on the regulation of endothelial cell functions and
n TRAIL-induced effects (Fig. 2). In the context of cancer TRAIL
lready represents a therapeutic option under evaluation used
ither alone or in combination with other molecules, in particular
ith ROS inducers, in order to trigger TRAIL-mediated apoptosis
Fig. 2). Nonetheless, it has been recently showed that mild oxida-
ive stress contributed to escape TRAIL-mediated apoptosis and
ediated TRAIL tolerance in an ovarian cancer model (Lu et al.,
016), in agreement with previous ﬁndings about the promoting
ole of ROS in TRAIL resistance (Choi et al., 2010). These contradic-
ory results, in line with the “dual” nature of TRAIL, highlight the
eed of further investigations to gain deeper insights on the mech-
nisms of TRAIL resistance and on the quantiﬁcation of the real
ntracellular ROS concentrations in relation to the modiﬁcations
nduced in ROS targets in each experimental/physiopathological
ondition. Further investigations are also required to clarify other
ssues such as the mechanisms of DR recruitment and the forma-
ion of redox signaling platforms upon TRAIL stimulation and the
unctions/effects induced by “local doses” of the TRAIL input.
Finally, new mechanistic comprehensions of the link between
OS and redox signaling with TRAIL-induced responses in speciﬁc
ell subsets in different physiopathological contexts, including can-
er, will help to understand the “life-death” signaling mediated by
RAIL, with signiﬁcant therapeutic implications.emistry & Cell Biology 81 (2016) 364–374 371
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.biocel.2016.09.
019.
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